Portal de Periódicos da CAPES

BIALLELIC INACTIVATION OF THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE IN SPORADIC RENAL CELL CARCINOMA

2002; Lippincott Williams & Wilkins; Volume: 167; Issue: 2 Part 1 Linguagem: Inglês

10.1016/s0022-5347(01)69132-8

1527-3792

KIMINARI HAMANO, Mariko Esumi, Hiroshi Igarashi, Kenji Chino, Junichi Mochida, HAJIME ISHIDAand, Kiyoki Okada,

Renal cell carcinoma treatment

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Feb 2002BIALLELIC INACTIVATION OF THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE IN SPORADIC RENAL CELL CARCINOMA KIMINARI HAMANO, MARIKO ESUMI, HIROSHI IGARASHI, KENJI CHINO, JUN′ICHI MOCHIDA, HAJIME ISHIDAand, and KIYOKI OKADA KIMINARI HAMANOKIMINARI HAMANO More articles by this author , MARIKO ESUMIMARIKO ESUMI More articles by this author , HIROSHI IGARASHIHIROSHI IGARASHI More articles by this author , KENJI CHINOKENJI CHINO More articles by this author , JUN′ICHI MOCHIDAJUN′ICHI MOCHIDA More articles by this author , HAJIME ISHIDAandHAJIME ISHIDAand More articles by this author , and KIYOKI OKADAKIYOKI OKADA More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)69132-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Somatic mutations of the von Hippel-Lindau tumor suppressor gene VHL and loss of heterozygosity of 3p25 to 26 have been well analyzed in renal cell carcinoma but it is not yet clear how often complete biallelic inactivation of VHL occurs in sporadic renal cell carcinoma. We improved the estimation of loss of heterozygosity of VHL and examined 2-hit inactivation of VHL based on loss of heterozygosity, mutation and methylation of sporadic renal cell carcinoma. Materials and Methods: DNA extracted from 59 Japanese sporadic renal cell carcinoma samples containing clear cells was examined for loss of heterozygosity of 4 intragenic markers of single nucleotide polymorphism and 2 extragenic microsatellite markers. Mutation was analyzed by sequencing amplified VHL DNA and methylation was analyzed by methylation specific polymerase chain reaction. Results: Four intragenic markers showed loss of heterozygosity in 13 of 22 samples (59.1%), whereas the 2 extragenic markers D3S1560 and D3S1317 showed loss of heterozygosity in 15 of 46 (32.6%) and 11 of 49 (22.4%), respectively. Considering loss of heterozygosity in 14 renal cell carcinomas informative at all 3 loci the incidence of loss of heterozygosity of VHL in renal cell carcinoma was estimated to be 73.5% or 25 of 34 cases. Mutations in VHL were found in 25 of 59 renal cell carcinomas (42.4%) and frame shift mutations in 68% of all mutations often occurred at nucleotide repeat sequences. Of the 34 loss of heterozygosity informative renal cell carcinoma 15 (44.1%) had 2-hit inactivation of VHL and 11 (32.4%) had 1-hit inactivation. Conclusions: The frequency of biallelic inactivation of VHL in sporadic renal cell carcinomas was unexpectedly low. According to the 2-hit theory of tumor suppressor genes another hit in VHL that to our knowledge remains unknown to date is thought to be involved in the development of renal cell carcinoma. References 1 : A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res1991; 51: 4707. Medline, Google Scholar 2 : Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: a breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res1995; 55: 5383. Medline, Google Scholar 3 : The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell1996; 84: 587. Crossref, Medline, Google Scholar 4 : Identification of the von Hippel-Lindau disease tumor suppressor gene. Science1993; 260: 1317. Crossref, Medline, Google Scholar 5 : Characteristic loss of heterozygosity in chromosome 3P and low frequency of replication errors in sporadic renal cell carcinoma. J Urol1999; 162: 614. Link, Google Scholar 6 : Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet1994; 7: 85. Crossref, Medline, Google Scholar 7 : Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res1994; 54: 2852. Medline, Google Scholar 8 : DNA methylation errors and cancer. Cancer Res1996; 56: 2463. Medline, Google Scholar 9 : UICC TNM Classification of Malignant Tumours. New York: Springer-Verlag1992. Google Scholar 10 : A PCR generated AccI RFLP in the 3′ untranslated region of the von Hippel-Lindau disease (VHL) tumour suppressor gene. Hum Mol Genet1994; 3: 390. Crossref, Medline, Google Scholar 11 : Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat1999; 13: 464. Crossref, Medline, Google Scholar 12 : Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene1994; 9: 1599. Medline, Google Scholar 13 : Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA1996; 93: 9821. Crossref, Medline, Google Scholar 14 : VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res2000; 60: 1942. Medline, Google Scholar 15 : Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer1998; 22: 200. Crossref, Medline, Google Scholar 16 : Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA1994; 91: 9700. Crossref, Medline, Google Scholar 17 : Inhibition of transcription elongation by the VHL tumor suppressor protein. Science1995; 269: 1402. Crossref, Medline, Google Scholar 18 : Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science1999; 284: 657. Crossref, Medline, Google Scholar 19 : Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol2000; 2: 423. Crossref, Medline, Google Scholar 20 : The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature1999; 399: 271. Crossref, Medline, Google Scholar 21 : The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell1998; 1: 959. Crossref, Medline, Google Scholar 22 : The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA1998; 95: 993. Crossref, Medline, Google Scholar 23 : The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem1997; 272: 27509. Crossref, Medline, Google Scholar 24 : Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem2000; 275: 20700. Crossref, Medline, Google Scholar 25 : Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem1998; 273: 26277. Crossref, Medline, Google Scholar 26 : An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Comm1999; 266: 43. Crossref, Medline, Google Scholar 27 : Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes Cancer1999; 26: 20. Crossref, Medline, Google Scholar From the Department of Pathology and Department Urology, Nihon University School of Medicine, Tokyo, Japan© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Chrabańska M, Szweda-Gandor N and Drozdzowska B (2023) Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell CarcinomaInternational Journal of Molecular Sciences, 10.3390/ijms24043778, VOL. 24, NO. 4, (3778) Cinque A, Minnei R, Floris M and Trevisani F (2022) The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?Cancers, 10.3390/cancers14215352, VOL. 14, NO. 21, (5352) Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker C and Dere R (2017) Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHLOncogene, 10.1038/onc.2016.495, VOL. 36, NO. 24, (3450-3463), Online publication date: 1-Jun-2017. Wang W, Tsou M, Chen H, Hsu W and Lai Y (2014) Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinomaBMC Research Notes, 10.1186/1756-0500-7-638, VOL. 7, NO. 1, Online publication date: 1-Dec-2014. Cerbone L, Recine F and Sternberg C (2014) Pharmacotherapy options for advanced renal cell carcinomaExpert Opinion on Orphan Drugs, 10.1517/21678707.2014.911079, VOL. 2, NO. 7, (643-652), Online publication date: 1-Jul-2014. Arreola A and Rathmell W (2013) Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects) Renal Cell Carcinoma, 10.1007/978-1-62703-062-5_13, (231-247), . Asakawa T, Esumi M, Endo S, Kida A and Ikeda M (2012) A mutation at IVS1 + 5 of the von Hippel-Lindau gene resulting in intron retention in transcripts is not pathogenic in a patient with a tongue cancer?: case reportBMC Medical Genetics, 10.1186/1471-2350-13-23, VOL. 13, NO. 1, Online publication date: 1-Dec-2012. Yamasaki T, Kamba T, Kanno T, Inoue T, Shibasaki N, Arakaki R, Yamada T, Kondo K, Kamoto T, Nishiyama H, Ogawa O and Nakamura E (2012) Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy Cancer Science, 10.1111/j.1349-7006.2012.02412.x, VOL. 103, NO. 11, (2027-2037), Online publication date: 1-Nov-2012. Xu L, Zhu Y, Xu J, Wu K, Li J, Xu W, Liu H, Wang S, Yin H, Chen L, Wang G and Lin Z (2012) Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signalingCancer Science, 10.1111/j.1349-7006.2012.02291.x, VOL. 103, NO. 7, (1253-1258), Online publication date: 1-Jul-2012. Salinas-Sánchez A, Giménez-Bachs J, Serrano-Oviedo L, Nam Cha S and Sánchez-Prieto R (2012) Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinomaActas Urológicas Españolas (English Edition), 10.1016/j.acuroe.2012.04.009, VOL. 36, NO. 2, (99-103), Online publication date: 1-Feb-2012. Salinas-Sánchez A, Giménez-Bachs J, Serrano-Oviedo L, Nam Cha S and Sánchez-Prieto R (2012) Papel de las proteínas quinasas activadas por mitógenos (MAPK) en el carcinoma de células renales esporádicoActas Urológicas Españolas, 10.1016/j.acuro.2011.07.013, VOL. 36, NO. 2, (99-103), Online publication date: 1-Feb-2012. Campbell S and Lane B (2012) Malignant Renal Tumors Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00049-9, (1413-1474.e33), . Moore L, Nickerson M, Brennan P, Toro J, Jaeger E, Rinsky J, Han S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt L, Lenz P, Karami S, Linehan W, Merino M, Chanock S, Boffetta P, Chow W, Waldman F, Rothman N and Maher E (2011) Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk FactorsPLoS Genetics, 10.1371/journal.pgen.1002312, VOL. 7, NO. 10, (e1002312) Young A, Craven R, Cohen D, Taylor C, Booth C, Harnden P, Cairns D, Astuti D, Gregory W, Maher E, Knowles M, Joyce A, Selby P and Banks R (2009) Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma Clinical Cancer Research, 10.1158/1078-0432.CCR-09-2131, VOL. 15, NO. 24, (7582-7592), Online publication date: 15-Dec-2009. Mochida J, Esumi M, Kitajima A and Okada K (2008) Allelic Loss Analysis of Tumor Suppressor Genes Regardless of Heterozygosity: von Hippel-Lindau Gene Loss in Renal Cell CarcinomaJournal of Urology, VOL. 180, NO. 2, (724-728), Online publication date: 1-Aug-2008. Asakawa T, Esumi M, Endo S, Kida A and Ikeda M (2008) Tongue cancer patients have a high frequency of allelic loss at thevon Hippel-Lindau gene and other loci on 3pCancer, 10.1002/cncr.23200, VOL. 112, NO. 3, (527-534), Online publication date: 1-Feb-2008. Bugalho M, Mendonça E, Costa P, Rosa Santos J, Silva E, Catarino A and Sobrinho L (2006) A multinodular goiter as the initial presentation of a renal cell carcinoma harbouring a novel VHL mutationBMC Endocrine Disorders, 10.1186/1472-6823-6-6, VOL. 6, NO. 1, Online publication date: 1-Dec-2006. Giménez-Bachs J, Salinas-Sánchez A, Sánchez-Sánchez F, Lorenzo-Romero J, Donate-Moreno M, Pastor-Navarro H, García-Olmo D, Escribano-Martínez J and Virseda-Rodríguez J (2006) Determination of vhl Gene Mutations in Sporadic Renal Cell CarcinomaEuropean Urology, 10.1016/j.eururo.2005.10.028, VOL. 49, NO. 6, (1051-1057), Online publication date: 1-Jun-2006. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang G, Kondo K, Nosé V and Kaelin W (2006) Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor ProteinThe American Journal of Pathology, 10.2353/ajpath.2006.050867, VOL. 168, NO. 2, (574-584), Online publication date: 1-Feb-2006. Miyazaki T and Takahashi M (2006) Hereditary Renal Cancer Imaging of Kidney Cancer, 10.1007/3-540-30003-1_15, (239-256), . van Houwelingen K, van Dijk B, Hulsbergen-van de Kaa C, Schouten L, Gorissen H, Schalken J, van den Brandt P and Oosterwijk E (2005) Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort studyBMC Cancer, 10.1186/1471-2407-5-57, VOL. 5, NO. 1, Online publication date: 1-Dec-2005. Strefford J, Stasevich I, Lane T, Lu Y, Oliver T and Young B (2005) A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinomaCancer Genetics and Cytogenetics, 10.1016/j.cancergencyto.2004.09.020, VOL. 159, NO. 1, (1-9), Online publication date: 1-May-2005. Kim W and Kaelin W (2004) Role of VHL Gene Mutation in Human Cancer Journal of Clinical Oncology, 10.1200/JCO.2004.05.061, VOL. 22, NO. 24, (4991-5004), Online publication date: 15-Dec-2004. Choyke P (2003) Imaging of hereditary renal cancerRadiologic Clinics of North America, 10.1016/S0033-8389(03)00068-X, VOL. 41, NO. 5, (1037-1051), Online publication date: 1-Sep-2003. NA X, WU G, RYAN C, SCHOEN S, di’SANTAGNESE P and MESSING E (2018) Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.Journal of Urology, VOL. 170, NO. 2, (588-592), Online publication date: 1-Aug-2003. Igarashi H, Esumi M, Ishida H and Okada K (2002) Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinomaCancer, 10.1002/cncr.10635, VOL. 95, NO. 1, (47-53), Online publication date: 1-Jul-2002. Volume 167Issue 2 Part 1February 2002Page: 713-717 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordscarcinoma, renal cellHippel-Lindau diseaseloss of heterozygositykidneygenes, suppressor tumorMetrics Author Information KIMINARI HAMANO More articles by this author MARIKO ESUMI More articles by this author HIROSHI IGARASHI More articles by this author KENJI CHINO More articles by this author JUN′ICHI MOCHIDA More articles by this author HAJIME ISHIDAand More articles by this author KIYOKI OKADA More articles by this author Expand All Advertisement PDF downloadLoading ...